Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors.
PET Clin
; 19(3): 341-349, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38658229
ABSTRACT
Peptide receptor radionuclide therapy (PRRT) has become mainstream therapy of metastatic neuroendocrine tumors not controlled by somatostatin analog therapy. Currently, beta particle-emitting radiopharmaceuticals are the mainstay of PRRT. Alpha particle-emitting radiopharmaceuticals have a theoretic advantage over beta emitters in terms of improved therapeutic efficacy due to higher cancer cell death and lower nontarget tissue radiation-induced adverse events due to shorter path length of alpha particles. We discuss the available evidence for and the role of alpha particle PRRT.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Receptores de Péptidos
/
Tumores Neuroendocrinos
/
Radiofármacos
/
Partículas alfa
Límite:
Humans
Idioma:
En
Revista:
PET Clin
Año:
2024
Tipo del documento:
Article